The "pediatric targeted therapy" (PTT) program aims to identify the presence and activity of druggable targets and evaluate the clinical benefit of a personalized treatment approach in relapsed or progressive tumors on an individual basis. 10 markers (HDAC2, HR23B, p-AKT, p-ERK, p-S6, p-EGFR, PDGFR-alpha/beta, p53 and BRAFV600E) were analyzed by immunohistochemistry. Pediatric patients with tumors independent of the histological diagnosis, with relapse or progression after treatment according to standard protocols were included. N = 61/145 (42

作者：Florian, Selt；Alica, Dei?；Andrey, Korshunov；David, Capper；Hendrik, Witt；Cornelis M, van Tilburg；David T W, Jones；Ruth, Witt；Felix, Sahm；David, Reuss；Christian, K?lsche；Jonas, Ecker；Ina, Oehme；Thomas, Hielscher；Andreas, von Deimling；Andreas E, Kulozik；Stefan M, Pfister；Olaf, Witt；Till, Milde

来源：Brain pathology (Zurich, Switzerland) 2016 年 26卷 4期